Assessment of the VENUSS and GRANT Models for Individual Prediction of Cancer-specific Survival in Surgically Treated Nonmetastatic Papillary Renal Cell Carcinoma

Albiges, 2018, Non–clear cell renal cell carcinomas: from shadow to light, J Clin Oncol, 36, 3624, 10.1200/JCO.2018.79.2531 Buti, 2012, Systemic adjuvant therapies in renal cell carcinoma, Oncol Rev, 6, 145, 10.4081/oncol.2012.e18 Breda, 2007, Patterns of recurrence and surveillance strategies for renal cell carcinoma following surgical resection, Expert Rev Anticancer Ther, 7, 847, 10.1586/14737140.7.6.847 Ljungberg, 1999, Follow-up guidelines for nonmetastatic renal cell carcinoma based on the occurrence of metastases after radical nephrectomy, BJU Int, 84, 405, 10.1046/j.1464-410x.1999.00202.x Kattan, 2001, A postoperative prognostic nomogram for renal cell carcinoma, J Urol, 166, 63, 10.1016/S0022-5347(05)66077-6 Zisman, 2001, Improved prognostication of renal cell carcinoma using an integrated staging system, J Clin Oncol, 19, 1649, 10.1200/JCO.2001.19.6.1649 Sorbellini, 2005, A postoperative prognostic nomogram predicting recurrence for patients with conventional clear cell renal cell carcinoma, J Urol, 173, 48, 10.1097/01.ju.0000148261.19532.2c Karakiewicz, 2007, Multi-institutional validation of a new renal cancer-specific survival nomogram, J Clin Oncol, 25, 1316, 10.1200/JCO.2006.06.1218 Ljungberg, 2022 Klatte, 2019, The VENUSS prognostic model to predict disease recurrence following surgery for non-metastatic papillary renal cell carcinoma: development and evaluation using the ASSURE prospective clinical trial cohort, BMC Med, 17, 182, 10.1186/s12916-019-1419-1 Erdem, 2022, External validation of the VENUSS prognostic model to predict recurrence after surgery in non-metastatic papillary renal cell carcinoma: a multi-institutional analysis, Urol Oncol, 40, 198.e9, 10.1016/j.urolonc.2022.01.006 Rosiello, 2022, Head-to-head comparison of all the prognostic models recommended by the European Association of Urology guidelines to predict oncologic outcomes in patients with renal cell carcinoma, Urol Oncol, 40, 271.e19, 10.1016/j.urolonc.2021.12.010 Passalacqua, 2014, Adjuvant low-dose interleukin-2 (IL-2) plus interferon-α (IFN-α) in operable renal cell carcinoma (RCC): a phase III, randomized, multicentre trial of the Italian Oncology Group for Clinical Research (GOIRC), J Immunother, 37, 440, 10.1097/CJI.0000000000000055 Buti, 2017, Validation of a new prognostic model to easily predict outcome in renal cell carcinoma: the GRANT score applied to the ASSURE trial population, Ann Oncol, 28, 2747, 10.1093/annonc/mdx492 Howlader N, Noone A, Krapcho M, et al. SEER cancer statistics review (CSR) 1975–2018. Bethesda, MD: National Cancer Institute; 2021. https://seer.cancer.gov/csr/1975_2017/. Vickers, 2006, Decision curve analysis: a novel method for evaluating prediction models, Med Decis Making, 26, 565, 10.1177/0272989X06295361 Moch, 2016, The 2016 WHO classification of tumours of the urinary system and male genital organs—part A: renal, penile, and testicular tumours, Eur Urol, 70, 93, 10.1016/j.eururo.2016.02.029 Heagerty, 2005, Survival model predictive accuracy and ROC curves, Biometrics, 61, 92, 10.1111/j.0006-341X.2005.030814.x Wilson A, Norden N. The R Project for Statistical Computing. https://www.r-project.org/. Collins, 2015, Transparent reporting of a multivariable prediction model for individual prognosis or diagnosis (TRIPOD): the TRIPOD statement, Eur Urol, 67, 1142, 10.1016/j.eururo.2014.11.025 Rosiello, 2020, Histotype predicts the rate of lymph node invasion at nephrectomy in patients with nonmetastatic renal cell carcinoma, Urol Oncol, 38, 537, 10.1016/j.urolonc.2020.01.013 Shuch, 2012, The surgical approach to multifocal renal cancers: hereditary syndromes, ipsilateral multifocality, and bilateral tumors, Urol Clin North Am, 39, 133, 10.1016/j.ucl.2012.01.006